VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | Dara plus dex in R/R myeloma patients with renal impairment

Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, discusses the results of the Phase II DARE study (NCT03450057), investigating the combination of daratumumab (dara) and dexamethasone (dex) in patients with relapsed/refractory (R/R) multiple myeloma with renal impairment. The study found that dara+dex achieved rapid hematologic responses in patients with R/R myeloma and severe renal impairments, with many patients also experiencing a major renal response. This line of treatment also resulted in impressive progression-free survival rates. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter